GSK3B and non-small cell lung carcinoma: The results reveal that the USP1 inhibitor SJB2-043 enhances E-cadherin, ZO-1, occludin, GSK3β, and p-β-catenin/β-catenin levels, while suppressing N-cadherin expression, suggesting that SJB2-043 inhibits NSCLC progression by modulating EMT and Wnt/β-catenin signaling.